About Zim Laboratories Limited.
Data last updated: 14 July 2026
Zim Laboratories Limited. is a public limited company based in Nagpur, Maharashtra, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 14 February 1984, the company has been in operation for over 42 years.
Registered with ROC Nagpur under CIN L99999MH1984PLC032172. Listed on BSE: 541400.
Capital: an authorised share capital of ₹75 Cr and a paid-up capital of ₹53.55 Cr. It is led by directors including Zulfiquar Murtaza Kamal and Prakash Pralahadrao Sapkal.
Last AGM: 27 June 2025. Financial statements filed for year ended 31 March 2025. Office: Sadoday Gyan(Ground Floor) Opp.Nadt Nelson Square, Nagpur, Maharashtra, India – 440013.
As per NSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹374.4 Cr, a decline of 1.22% compared to the previous year. The net worth stands at ₹296.15 Cr (up 17.41% YoY). Total assets are valued at ₹539.39 Cr (up 14.27% YoY).
The company has a workforce of approximately 586 employees as per the latest available data. Its group structure includes 2 subsidiaries.
The company is associated with 1 brand - Zim Labs. As per MCA filings, the company has open charges of ₹206.19 Cr and satisfied charges of ₹537.82 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website zimlab.in.
-
EmailLocked
-
TelephoneLocked
-
Website
-
Social Media
-
Registered AddressSadoday Gyan(Ground Floor) Opp.Nadt Nelson Square, Nagpur, Maharashtra, India – 440013
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Zim Laboratories Limited.
Zim Laboratories Limited. has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L99999MH1984PLC032172, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L99999MH1984PLC032172 | Current |
| U99999MH1984PLC032172 | Previous |
| L99999MH1984PTC032172 | Previous |
Associated Brands with Zim Laboratories Limited.
Zim Laboratories Limited. operates one associated brand: Zim Labs. These brands represent Zim Laboratories Limited.'s diversified market presence and brand portfolio.
Competitors & Alternatives of Zim Laboratories Limited.
Brands and companies operating in the same space as Zim Laboratories Limited. include Inventia Healthcare, Lotus, Contract Pharmacal Corp. and 6 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
|
|
Oral solid drug delivery systems are manufactured and developed. | Mumbai, India, India | 1985 |
|
|
Contract manufacturing for oral solid formulations is offered. | Taipei, Taiwan, Taiwan | 1966 |
|
|
Product development, manufacturing and packaging services | Hauppauge, United States, United States | 1971 |
|
|
CDMO manufacturing solid drugs | Lawrence Township, United States, United States | 2015 |
|
|
Company developing small molecules & eukaryotic cell based recombinant protein drugs | Suzhou, China, China | 2009 |
|
|
Provides contract manufacturing services for food, pharmaceuticals, and related products globally. | Ahmedabad, India, India | 1984 |
|
|
Dosage forms are delivered for preclinical, clinical, and commercial supply. | Morristown, United States, United States | 1875 |
|
|
Turnkey development services for solid dosage forms are provided. | Cumberland, United States, United States | 2001 |
|
|
Offers a full range of solid dose manufacturing and packaging | Norwich, United States, United States | 1887 |
Business Activity of Zim Laboratories Limited.
Zim Laboratories Limited. is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details for Zim Laboratories Limited.
Turnover contribution percentages and historical activity changes require an active report plan.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Auditor Details of Zim Laboratories Limited.
Zim Laboratories Limited. is audited by Deloitte Haskins & Sells LLP (ICAI peer reviewed, certificate valid till 2027-07-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| Deloitte Haskins & Sells LLP (ICAI peer reviewed, certificate valid till 2027-07-31) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Zim Laboratories Limited.
Zim Laboratories Limited. is currently managed by 8 directors, with 14 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Zulfiquar Murtaza Kamal
Also directs:
Zim Health Technologies Limited, Zim Thinorals Private Limited, Falcon Knowledge Services Private Limited and 1 more
|
Whole-Time Director | 19 Oct 2012 | 13 Years 10 Months | Current |
|
Prakash Pralahadrao Sapkal
Also directs:
Zim Thinorals Private Limited
|
Whole-Time Director | 22 Nov 2013 | 12 Years 9 Months | Current |
| Niraj Pukhraj Dhadiwal | Whole-Time Director | 22 Nov 2013 | 12 Years 9 Months | Current |
| Kavita Loya | Director | 21 Sep 2017 | 8 Years 11 Months | Current |
| Padmakar Shrinivas Joshi | Director | 21 Sep 2017 | 8 Years 11 Months | Current |
|
Anwar Siraj Daud
Also directs:
Zim Health Technologies Limited, Zim Thinorals Private Limited
|
Managing Director | 01 Apr 2009 | 17 Years 4 Months | Current |
Financials of Zim Laboratories Limited. FY 2026 filings available
Zim Laboratories Limited. reported revenue of ₹374.4 Cr (down 1.22% YoY) for FY 2026.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Revenue from Operations | ₹374.4 Cr | ₹379.03 Cr | ₹367.42 Cr | ₹398.53 Cr |
| Other Income | ₹11.38 Cr | ₹5.78 Cr | ₹5.18 Cr | ₹6.41 Cr |
| Total Income | ₹385.78 Cr | ₹384.82 Cr | ₹372.61 Cr | ₹404.94 Cr |
| Cost of Materials Consumed | ₹164.05 Cr | ₹155 Cr | ₹177.7 Cr | ₹164.98 Cr |
| Purchases of Stock-in-Trade | ₹7.47 Cr | ₹11.58 Cr | ₹7.8 Cr | ₹17.39 Cr |
| Changes in Inventories | -₹6.14 Cr | ₹1.27 Cr | -₹14.05 Cr | ₹16.46 Cr |
| Employee Benefit Expense | ₹63.9 Cr | ₹60.76 Cr | ₹53.34 Cr | ₹49.32 Cr |
| Finance Costs | ₹13.2 Cr | ₹11.39 Cr | ₹6.92 Cr | ₹5.58 Cr |
| Depreciation & Amortisation | ₹19.98 Cr | ₹20.11 Cr | ₹15.95 Cr | ₹17.47 Cr |
| Other Expenses | ₹115.11 Cr | ₹106.7 Cr | ₹101.31 Cr | ₹98.38 Cr |
| Total Expenses | ₹377.57 Cr | ₹366.81 Cr | ₹348.97 Cr | ₹369.59 Cr |
| Profit Before Exceptional Items & Tax | ₹8.21 Cr | ₹18.01 Cr | ₹23.64 Cr | ₹35.36 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹8.21 Cr | ₹18.01 Cr | ₹23.64 Cr | ₹35.36 Cr |
| Total Tax Expense | ₹2.37 Cr | ₹5.84 Cr | ₹6.4 Cr | ₹10.92 Cr |
| Net Profit | ₹5.84 Cr | ₹12.17 Cr | ₹17.25 Cr | ₹24.43 Cr |
| attributable to Owners | ₹5.84 Cr | ₹12.17 Cr | ₹17.25 Cr | ₹24.43 Cr |
| attributable to NCI | ₹0 | -₹2,000 | -₹1,000 | ₹0 |
| Other Comprehensive Income | ₹2.11 Cr | -₹2.75 Lakh | -₹24.9 Lakh | ₹67.7 Lakh |
| Total Comprehensive Income | ₹7.94 Cr | ₹12.14 Cr | ₹17 Cr | ₹25.11 Cr |
| EBITDA (computed) | ₹41.39 Cr | ₹49.51 Cr | ₹46.52 Cr | ₹58.4 Cr |
| Basic EPS | ₹1.19 | ₹2.50 | ₹3.54 | ₹5.01 |
| Diluted EPS | ₹1.19 | ₹2.50 | ₹3.54 | ₹5.01 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹539.39 Cr | ₹472.02 Cr | ₹446.82 Cr | ₹341.58 Cr |
| Non-current Assets | ₹263.58 Cr | ₹240.72 Cr | ₹219.17 Cr | ₹150.63 Cr |
| Current Assets | ₹275.81 Cr | ₹231.31 Cr | ₹227.65 Cr | ₹190.95 Cr |
| Property, Plant & Equipment | ₹156.43 Cr | ₹158.34 Cr | ₹156.93 Cr | ₹103.72 Cr |
| Inventories | ₹93.77 Cr | ₹86.47 Cr | ₹81.26 Cr | ₹53.71 Cr |
| Trade Receivables | ₹109.04 Cr | ₹106.92 Cr | ₹100.17 Cr | ₹95.25 Cr |
| Cash & Equivalents | ₹25.12 Cr | ₹1.95 Cr | ₹9.6 Cr | ₹6.42 Cr |
| Equity (Net Worth) | ₹296.15 Cr | ₹252.24 Cr | ₹238.75 Cr | ₹200.35 Cr |
| Equity Share Capital | ₹53.5 Cr | ₹48.73 Cr | ₹48.73 Cr | ₹48.73 Cr |
| Borrowings (Non-current) | ₹41.59 Cr | ₹40.3 Cr | ₹35.6 Cr | ₹24.62 Cr |
| Borrowings (Current) | ₹81.4 Cr | ₹71.86 Cr | ₹70.75 Cr | ₹34.94 Cr |
| Total Debt (computed) | ₹122.98 Cr | ₹112.17 Cr | ₹106.35 Cr | ₹59.57 Cr |
| Current Liabilities | ₹190.39 Cr | ₹166.36 Cr | ₹159.43 Cr | ₹110.79 Cr |
| Total Liabilities | ₹243.23 Cr | ₹219.79 Cr | ₹208.08 Cr | ₹141.23 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Operating Cash Flow | ₹49.53 Cr | ₹41.15 Cr | ₹16.28 Cr | ₹37.52 Cr |
| Investing Cash Flow | -₹56.35 Cr | -₹39.93 Cr | -₹73.01 Cr | -₹36.2 Cr |
| Financing Cash Flow | ₹28.19 Cr | -₹9.1 Cr | ₹59.53 Cr | ₹54.56 Lakh |
| Capital Expenditure | ₹44.39 Cr | ₹40.8 Cr | ₹73.92 Cr | ₹36.67 Cr |
| Free Cash Flow (computed) | ₹5.15 Cr | ₹35.69 Lakh | -₹57.65 Cr | ₹85.16 Lakh |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | ₹23.18 Cr | -₹7.65 Cr | ₹3.18 Cr | ₹3 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹105.27 Cr | ₹108.66 Cr | ₹88.71 Cr | ₹71.76 Cr | ₹108.73 Cr | ₹96.33 Cr | ₹92.14 Cr | ₹81.82 Cr | ₹117.86 Cr | ₹96.29 Cr | ₹85.83 Cr | ₹67.44 Cr |
| Other Income | ₹6.16 Cr | ₹1.7 Cr | ₹2.04 Cr | ₹1.48 Cr | ₹1.71 Cr | ₹1.75 Cr | ₹1.32 Cr | ₹99.89 Lakh | ₹1.53 Cr | ₹1.11 Cr | ₹1.42 Cr | ₹1.12 Cr |
| Total Income | ₹111.44 Cr | ₹110.36 Cr | ₹90.75 Cr | ₹73.23 Cr | ₹110.44 Cr | ₹98.08 Cr | ₹93.46 Cr | ₹82.82 Cr | ₹119.4 Cr | ₹97.4 Cr | ₹87.25 Cr | ₹68.56 Cr |
| Cost of Materials Consumed | ₹49.7 Cr | ₹43.23 Cr | ₹43.5 Cr | ₹27.62 Cr | ₹48.6 Cr | ₹39.88 Cr | ₹35.52 Cr | ₹31.01 Cr | ₹53.49 Cr | ₹51.51 Cr | ₹40.96 Cr | ₹31.74 Cr |
| Purchases of Stock-in-Trade | ₹2.36 Cr | ₹58.68 Lakh | ₹2.93 Cr | ₹1.59 Cr | ₹3.3 Cr | ₹2.49 Cr | ₹3.14 Cr | ₹2.66 Cr | ₹2.12 Cr | ₹3.01 Cr | ₹2.04 Cr | ₹63.09 Lakh |
| Changes in Inventories | -₹4.94 Cr | ₹4.78 Cr | -₹6.78 Cr | ₹79.86 Lakh | -₹3.64 Cr | -₹1.11 Cr | ₹3.45 Cr | ₹2.56 Cr | ₹58.65 Lakh | -₹10.3 Cr | -₹3.08 Cr | -₹1.26 Cr |
| Employee Benefit Expense | ₹17.39 Cr | ₹15.58 Cr | ₹16.32 Cr | ₹14.61 Cr | ₹16.32 Cr | ₹14.47 Cr | ₹15.45 Cr | ₹14.51 Cr | ₹14.71 Cr | ₹13.17 Cr | ₹12.83 Cr | ₹12.63 Cr |
| Finance Costs | ₹3.31 Cr | ₹3.43 Cr | ₹3.16 Cr | ₹3.3 Cr | ₹2.91 Cr | ₹2.73 Cr | ₹2.89 Cr | ₹2.86 Cr | ₹2.28 Cr | ₹1.7 Cr | ₹1.22 Cr | ₹1.73 Cr |
| Depreciation & Amortisation | ₹5.1 Cr | ₹5.03 Cr | ₹4.98 Cr | ₹4.86 Cr | ₹5.29 Cr | ₹4.88 Cr | ₹5 Cr | ₹4.94 Cr | ₹3.91 Cr | ₹3.94 Cr | ₹4.09 Cr | ₹4.03 Cr |
| Other Expenses | ₹33.56 Cr | ₹31.68 Cr | ₹26.99 Cr | ₹22.88 Cr | ₹29.56 Cr | ₹29.04 Cr | ₹25.05 Cr | ₹23.05 Cr | ₹31.31 Cr | ₹27.37 Cr | ₹23.76 Cr | ₹18.87 Cr |
| Total Expenses | ₹106.49 Cr | ₹104.31 Cr | ₹91.1 Cr | ₹75.66 Cr | ₹102.33 Cr | ₹92.38 Cr | ₹90.5 Cr | ₹81.59 Cr | ₹108.4 Cr | ₹90.39 Cr | ₹81.8 Cr | ₹68.37 Cr |
| Profit Before Exceptional Items & Tax | ₹4.94 Cr | ₹6.05 Cr | -₹34.38 Lakh | -₹2.43 Cr | ₹8.11 Cr | ₹5.7 Cr | ₹2.96 Cr | ₹1.23 Cr | ₹11 Cr | ₹7.01 Cr | ₹5.44 Cr | ₹18.54 Lakh |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹4.94 Cr | ₹6.05 Cr | -₹34.38 Lakh | -₹2.43 Cr | ₹8.11 Cr | ₹5.7 Cr | ₹2.96 Cr | ₹1.23 Cr | ₹11 Cr | ₹7.01 Cr | ₹5.44 Cr | ₹18.54 Lakh |
| Total Tax Expense | ₹1.2 Cr | ₹1.65 Cr | ₹8.08 Lakh | -₹55.71 Lakh | ₹3.22 Cr | ₹1.7 Cr | ₹58.15 Lakh | ₹33.61 Lakh | ₹2.91 Cr | ₹2.23 Cr | ₹1.29 Cr | -₹4.12 Lakh |
| Net Profit | ₹3.74 Cr | ₹4.4 Cr | -₹42.46 Lakh | -₹1.87 Cr | ₹4.88 Cr | ₹4 Cr | ₹2.38 Cr | ₹89.83 Lakh | ₹8.09 Cr | ₹4.78 Cr | ₹4.15 Cr | ₹22.66 Lakh |
| attributable to Owners | ₹3.74 Cr | ₹4.4 Cr | -₹42.46 Lakh | -₹1.87 Cr | ₹4.88 Cr | ₹4 Cr | ₹2.38 Cr | ₹89.83 Lakh | ₹8.09 Cr | ₹4.78 Cr | ₹4.15 Cr | ₹22.66 Lakh |
| attributable to NCI | ₹1,000 | -₹1,000 | ₹0 | ₹0 | -₹2,000 | ₹0 | ₹0 | ₹0 | -₹1,000 | ₹0 | ₹0 | ₹0 |
| Other Comprehensive Income | ₹49.63 Lakh | ₹86.67 Lakh | ₹32.48 Lakh | ₹41.89 Lakh | -₹39.24 Lakh | ₹28.25 Lakh | ₹15.29 Lakh | -₹7.05 Lakh | -₹7.06 Lakh | -₹4.21 Lakh | ₹77,000 | -₹14.4 Lakh |
| Total Comprehensive Income | ₹4.24 Cr | ₹5.26 Cr | -₹9.98 Lakh | -₹1.46 Cr | ₹4.49 Cr | ₹4.28 Cr | ₹2.53 Cr | ₹82.78 Lakh | ₹8.02 Cr | ₹4.74 Cr | ₹4.16 Cr | ₹8.26 Lakh |
| EBITDA (computed) | ₹13.35 Cr | ₹14.51 Cr | ₹7.8 Cr | ₹5.74 Cr | ₹16.31 Cr | ₹13.32 Cr | ₹10.85 Cr | ₹9.04 Cr | ₹17.18 Cr | ₹12.65 Cr | ₹10.75 Cr | ₹5.95 Cr |
| Basic EPS | ₹0.76 | ₹0.90 | ₹-0.09 | ₹-0.38 | ₹1.01 | ₹0.82 | ₹0.49 | ₹0.18 | ₹1.66 | ₹0.98 | ₹0.85 | ₹0.05 |
| Diluted EPS | ₹0.76 | ₹0.90 | ₹-0.09 | ₹-0.38 | ₹1.01 | ₹0.82 | ₹0.49 | ₹0.18 | ₹1.66 | ₹0.98 | ₹0.85 | ₹0.05 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Revenue from Operations | ₹370.48 Cr | ₹375.64 Cr | ₹365.47 Cr | ₹396.53 Cr |
| Other Income | ₹11.39 Cr | ₹5.62 Cr | ₹4.69 Cr | ₹6.43 Cr |
| Total Income | ₹381.87 Cr | ₹381.26 Cr | ₹370.16 Cr | ₹402.96 Cr |
| Cost of Materials Consumed | ₹163.19 Cr | ₹155 Cr | ₹177.7 Cr | ₹164.98 Cr |
| Purchases of Stock-in-Trade | ₹7.47 Cr | ₹11.58 Cr | ₹7.8 Cr | ₹17.39 Cr |
| Changes in Inventories | -₹6.14 Cr | ₹1.27 Cr | -₹14.05 Cr | ₹16.46 Cr |
| Employee Benefit Expense | ₹60.1 Cr | ₹56.41 Cr | ₹50.81 Cr | ₹46.47 Cr |
| Finance Costs | ₹13.2 Cr | ₹11.39 Cr | ₹6.92 Cr | ₹5.58 Cr |
| Depreciation & Amortisation | ₹19.37 Cr | ₹19.89 Cr | ₹14.83 Cr | ₹16.13 Cr |
| Other Expenses | ₹116.29 Cr | ₹108.11 Cr | ₹103.12 Cr | ₹100.03 Cr |
| Total Expenses | ₹373.47 Cr | ₹363.64 Cr | ₹347.12 Cr | ₹367.04 Cr |
| Profit Before Exceptional Items & Tax | ₹8.4 Cr | ₹17.61 Cr | ₹23.04 Cr | ₹35.92 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹8.4 Cr | ₹17.61 Cr | ₹23.04 Cr | ₹35.92 Cr |
| Total Tax Expense | ₹2.44 Cr | ₹5.87 Cr | ₹6.28 Cr | ₹10.91 Cr |
| Net Profit | ₹5.97 Cr | ₹11.74 Cr | ₹16.76 Cr | ₹25.01 Cr |
| Other Comprehensive Income | -₹9.82 Lakh | -₹53.84 Lakh | -₹38.19 Lakh | -₹46.16 Lakh |
| Total Comprehensive Income | ₹5.87 Cr | ₹11.21 Cr | ₹16.37 Cr | ₹24.55 Cr |
| EBITDA (computed) | ₹40.97 Cr | ₹48.89 Cr | ₹44.79 Cr | ₹57.62 Cr |
| Basic EPS | ₹1.22 | ₹2.41 | ₹3.44 | ₹5.13 |
| Diluted EPS | ₹1.22 | ₹2.41 | ₹3.44 | ₹5.13 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹525.2 Cr | ₹464.39 Cr | ₹442.5 Cr | ₹334.87 Cr |
| Non-current Assets | ₹272.77 Cr | ₹248.04 Cr | ₹224.79 Cr | ₹156.23 Cr |
| Current Assets | ₹252.43 Cr | ₹216.35 Cr | ₹217.71 Cr | ₹178.64 Cr |
| Property, Plant & Equipment | ₹156.37 Cr | ₹158.28 Cr | ₹156.92 Cr | ₹103.69 Cr |
| Inventories | ₹93.77 Cr | ₹86.47 Cr | ₹81.26 Cr | ₹53.71 Cr |
| Trade Receivables | ₹92.28 Cr | ₹93.68 Cr | ₹100.09 Cr | ₹88.36 Cr |
| Cash & Equivalents | ₹18.8 Cr | ₹36.36 Lakh | ₹17.35 Lakh | ₹1.11 Cr |
| Equity (Net Worth) | ₹286.35 Cr | ₹244.51 Cr | ₹231.95 Cr | ₹194.18 Cr |
| Equity Share Capital | ₹53.5 Cr | ₹48.73 Cr | ₹48.73 Cr | ₹48.73 Cr |
| Borrowings (Non-current) | ₹41.59 Cr | ₹40.3 Cr | ₹35.6 Cr | ₹24.62 Cr |
| Borrowings (Current) | ₹81.4 Cr | ₹71.86 Cr | ₹70.75 Cr | ₹34.94 Cr |
| Total Debt (computed) | ₹122.98 Cr | ₹112.17 Cr | ₹106.35 Cr | ₹59.57 Cr |
| Current Liabilities | ₹186.01 Cr | ₹166.2 Cr | ₹161.9 Cr | ₹110.24 Cr |
| Total Liabilities | ₹238.85 Cr | ₹219.87 Cr | ₹210.55 Cr | ₹140.69 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Operating Cash Flow | ₹47.66 Cr | ₹50.6 Cr | ₹11.47 Cr | ₹35.23 Cr |
| Investing Cash Flow | -₹57.41 Cr | -₹41.31 Cr | -₹71.94 Cr | -₹35.21 Cr |
| Financing Cash Flow | ₹28.19 Cr | -₹9.1 Cr | ₹59.53 Cr | ₹54.56 Lakh |
| Capital Expenditure | ₹41.63 Cr | ₹37.92 Cr | ₹72.59 Cr | ₹35.67 Cr |
| Free Cash Flow (computed) | ₹6.03 Cr | ₹12.69 Cr | -₹61.12 Cr | -₹44.24 Lakh |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | ₹18.43 Cr | ₹19.01 Lakh | -₹93.63 Lakh | ₹56.76 Lakh |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹102.85 Cr | ₹107.81 Cr | ₹88.39 Cr | ₹71.43 Cr | ₹108.52 Cr | ₹95.4 Cr | ₹89.72 Cr | ₹82 Cr | ₹117.39 Cr | ₹95.82 Cr | ₹85.26 Cr | ₹67.01 Cr |
| Other Income | ₹6.16 Cr | ₹1.71 Cr | ₹2.04 Cr | ₹1.48 Cr | ₹1.55 Cr | ₹1.76 Cr | ₹1.32 Cr | ₹98.03 Lakh | ₹1.53 Cr | ₹1.11 Cr | ₹1.42 Cr | ₹63.24 Lakh |
| Total Income | ₹109.01 Cr | ₹109.52 Cr | ₹90.44 Cr | ₹72.9 Cr | ₹110.07 Cr | ₹97.16 Cr | ₹91.04 Cr | ₹82.98 Cr | ₹118.92 Cr | ₹96.93 Cr | ₹86.68 Cr | ₹67.64 Cr |
| Cost of Materials Consumed | ₹48.85 Cr | ₹43.23 Cr | ₹43.5 Cr | ₹27.62 Cr | ₹48.6 Cr | ₹39.88 Cr | ₹35.52 Cr | ₹31.01 Cr | ₹53.49 Cr | ₹51.51 Cr | ₹40.96 Cr | ₹31.74 Cr |
| Purchases of Stock-in-Trade | ₹2.36 Cr | ₹58.68 Lakh | ₹2.93 Cr | ₹1.59 Cr | ₹3.3 Cr | ₹2.49 Cr | ₹3.14 Cr | ₹2.66 Cr | ₹2.12 Cr | ₹3.01 Cr | ₹2.04 Cr | ₹63.09 Lakh |
| Changes in Inventories | -₹5.12 Cr | ₹4.97 Cr | -₹6.78 Cr | ₹79.86 Lakh | -₹3.64 Cr | -₹1.11 Cr | ₹2.87 Cr | ₹3.14 Cr | ₹58.65 Lakh | -₹10.3 Cr | -₹3.08 Cr | -₹1.26 Cr |
| Employee Benefit Expense | ₹16.28 Cr | ₹14.79 Cr | ₹15.46 Cr | ₹13.57 Cr | ₹15.33 Cr | ₹13.16 Cr | ₹14.44 Cr | ₹13.48 Cr | ₹14.12 Cr | ₹12.32 Cr | ₹12.24 Cr | ₹12.12 Cr |
| Finance Costs | ₹3.31 Cr | ₹3.43 Cr | ₹3.16 Cr | ₹3.3 Cr | ₹2.91 Cr | ₹2.73 Cr | ₹2.89 Cr | ₹2.86 Cr | ₹2.28 Cr | ₹1.7 Cr | ₹1.22 Cr | ₹1.73 Cr |
| Depreciation & Amortisation | ₹4.9 Cr | ₹4.85 Cr | ₹4.83 Cr | ₹4.79 Cr | ₹5.23 Cr | ₹4.77 Cr | ₹4.97 Cr | ₹4.92 Cr | ₹3.87 Cr | ₹3.58 Cr | ₹3.72 Cr | ₹3.66 Cr |
| Other Expenses | ₹33.91 Cr | ₹31.75 Cr | ₹27.12 Cr | ₹23.51 Cr | ₹29.69 Cr | ₹29.22 Cr | ₹25.37 Cr | ₹23.84 Cr | ₹31.65 Cr | ₹28.1 Cr | ₹24.13 Cr | ₹19.23 Cr |
| Total Expenses | ₹104.49 Cr | ₹103.59 Cr | ₹90.21 Cr | ₹75.19 Cr | ₹101.42 Cr | ₹91.13 Cr | ₹89.19 Cr | ₹81.9 Cr | ₹108.12 Cr | ₹89.92 Cr | ₹81.23 Cr | ₹67.86 Cr |
| Profit Before Exceptional Items & Tax | ₹4.53 Cr | ₹5.93 Cr | ₹22.81 Lakh | -₹2.28 Cr | ₹8.65 Cr | ₹6.03 Cr | ₹1.85 Cr | ₹1.08 Cr | ₹10.8 Cr | ₹7.01 Cr | ₹5.45 Cr | -₹22.26 Lakh |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹4.53 Cr | ₹5.93 Cr | ₹22.81 Lakh | -₹2.28 Cr | ₹8.65 Cr | ₹6.03 Cr | ₹1.85 Cr | ₹1.08 Cr | ₹10.8 Cr | ₹7.01 Cr | ₹5.45 Cr | -₹22.26 Lakh |
| Total Tax Expense | ₹1.24 Cr | ₹1.67 Cr | ₹11.21 Lakh | -₹59.1 Lakh | ₹3.23 Cr | ₹1.68 Cr | ₹63.59 Lakh | ₹32.52 Lakh | ₹2.91 Cr | ₹2.18 Cr | ₹1.27 Cr | -₹7.96 Lakh |
| Net Profit | ₹3.28 Cr | ₹4.26 Cr | ₹11.6 Lakh | -₹1.69 Cr | ₹5.42 Cr | ₹4.35 Cr | ₹1.22 Cr | ₹75.9 Lakh | ₹7.89 Cr | ₹4.83 Cr | ₹4.18 Cr | -₹14.3 Lakh |
| Other Comprehensive Income | ₹30.56 Lakh | -₹13.46 Lakh | -₹13.46 Lakh | -₹13.46 Lakh | -₹25.19 Lakh | -₹9.55 Lakh | -₹9.55 Lakh | -₹9.55 Lakh | -₹3.56 Lakh | -₹11.54 Lakh | -₹11.55 Lakh | -₹11.54 Lakh |
| Total Comprehensive Income | ₹3.59 Cr | ₹4.12 Cr | -₹1.86 Lakh | -₹1.83 Cr | ₹5.17 Cr | ₹4.25 Cr | ₹1.12 Cr | ₹66.35 Lakh | ₹7.85 Cr | ₹4.71 Cr | ₹4.06 Cr | -₹25.84 Lakh |
| EBITDA (computed) | ₹12.74 Cr | ₹14.21 Cr | ₹8.22 Cr | ₹5.81 Cr | ₹16.79 Cr | ₹13.53 Cr | ₹9.71 Cr | ₹8.86 Cr | ₹16.96 Cr | ₹12.28 Cr | ₹10.38 Cr | ₹5.17 Cr |
| Basic EPS | ₹0.67 | ₹0.87 | ₹0.03 | ₹-0.35 | ₹1.11 | ₹0.89 | ₹0.25 | ₹0.16 | ₹1.62 | ₹0.99 | ₹0.86 | ₹-0.03 |
| Diluted EPS | ₹0.67 | ₹0.87 | ₹0.03 | ₹-0.35 | ₹1.11 | ₹0.89 | ₹0.25 | ₹0.16 | ₹1.62 | ₹0.99 | ₹0.86 | ₹-0.03 |
Shareholding Pattern of Zim Laboratories Limited.
As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 30.35%, domestic institutional investors hold 0.07%, retail and other public shareholders hold 69.58% of Zim Laboratories Limited.. The company had 16,636 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 30.35% | 33.26% | 33.26% | 33.26% | 33.26% | 33.26% |
| Public | 69.65% | 66.74% | 66.74% | 66.74% | 66.74% | 66.74% |
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Promoters | 30.35% | 33.26% | 33.26% | 33.26% |
| Public | 69.65% | 66.74% | 66.74% | 66.74% |
| Promoter change (YoY, %pts) | -2.91 | +0.00 | +0.00 | - |
Board & Governance of Zim Laboratories Limited.
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Zim Laboratories Limited. has 8 directors - 4 independent and 4 executive. The board is chaired by Anwar Daud.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| Anwar Daud | Executive Director · MD · Chairperson | 2002-06-30 | 1 |
| Zulfiquar Murtuza Kamal | Executive Director | 2012-10-19 | 1 |
| Niraj Pukhraj Dhadiwal | Executive Director | 2013-11-22 | 1 |
| Prakash Pralahadrao Sapkal | Executive Director | 2013-11-22 | 1 |
| Kavita Loya | Non-Executive - Independent Director | 2017-09-21 | 1 |
| Padmakar Shrinivas Joshi | Non-Executive - Independent Director | 2017-09-21 | 1 |
| Kamlesh Bajirao Shende | Non-Executive - Independent Director | 2022-04-01 | 1 |
| Ashok Bhatia | Non-Executive - Independent Director | 2025-04-01 | 2 |
| Committee | Members |
|---|---|
| Audit Committee | Kavita Loya (Chairperson), Padmakar Shrinivas Joshi, Zulfiquar Murtuza Kamal |
| Nomination and remuneration committee | Padmakar Shrinivas Joshi (Chairperson), Kavita Loya, Ashok Bhatia, Anwar Daud |
| Stakeholders Relationship Committee | Kavita Loya (Chairperson), Kamlesh Bajirao Shende, Prakash Pralahadrao Sapkal |
| Risk Management Committee | Padmakar Shrinivas Joshi (Chairperson), Kamlesh Bajirao Shende, Kavita Loya, Anwar Daud |
| Corporate Social Responsibility Committee | Kamlesh Bajirao Shende (Chairperson), Padmakar Shrinivas Joshi, Niraj Pukhraj Dhadiwal |
Group Structure of Zim Laboratories Limited.
Zim Laboratories Limited. has 2 subsidiary companies. This group structure data is as of FY 2024. The corporate group structure reflects Zim Laboratories Limited.'s business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Zim Health Technologies Limited | U24100MH2009PLC193240 | - |
| Zim Thinorals Private Limited | U24297MH2021PTC360634 | - |
Showing major subsidiaries. Total: 2.
Charges & Borrowings of Zim Laboratories Limited.
| Date | Lender | Amount | Status |
|---|---|---|---|
| 31 Oct 2023 | Others | ₹25 Cr | Open |
| 01 Feb 2013 | Bank of India | ₹181.19 Cr | Open |
| 31 Jan 2026 | Others | ₹7 Cr | Satisfied |
| 28 Apr 2025 | Bank of India | ₹6.5 Cr | Satisfied |
| 29 May 2024 | Others | ₹16 Cr | Satisfied |
Total charge records: 52 View all charges
Employees and EPFO Compliance at Zim Laboratories Limited.
Zim Laboratories Limited. has a workforce of 586 employees as of Jan 19, 2026.
Employee and EPFO history for Zim Laboratories Limited.
Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
GST Compliance of Zim Laboratories Limited.
GST registrations and filing compliance for Zim Laboratories Limited.
State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
Credit Ratings, Litigation & Regulatory Alerts for Zim Laboratories Limited.
Credit ratings, litigation, and regulatory alerts for Zim Laboratories Limited.
Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Zim Laboratories Limited.
MSME payment history for Zim Laboratories Limited.
Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Zim Laboratories Limited.
Corporate group structure for Zim Laboratories Limited.
Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Zim Laboratories Limited.
MCA filings and documents for Zim Laboratories Limited.
Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Recent Activity on Zim Laboratories Limited.
Recent News on Zim Laboratories Limited.
Frequently Asked Questions about Zim Laboratories Limited.
Zim Laboratories Limited. is an active public limited company in the pharma sector based in Nagpur, Maharashtra, India. It was incorporated on 14 February 1984 (42+ years old) and is registered under CIN L99999MH1984PLC032172. Listed on BSE: 541400. The company has 586 employees.
Zim Laboratories Limited. reported revenue of ₹374.4 Cr for FY 2026 (down 1.22% YoY) based on consolidated NSE filings.
The current directors of Zim Laboratories Limited. are:
- Zulfiquar Murtaza Kamal - Whole-Time Director
- Prakash Pralahadrao Sapkal - Whole-Time Director
- Niraj Pukhraj Dhadiwal - Whole-Time Director
- Kavita Loya - Director
- Padmakar Shrinivas Joshi - Director
- Anwar Siraj Daud - Managing Director
- Kamlesh Bajirao Shende - Director
- Ashok Bhatia - Director
The primary industry of Zim Laboratories Limited. is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Yes. Zim Laboratories Limited. is listed on BSE with code 541400.
Zim Laboratories Limited. can be reached at the registered office: Sadoday GyanGround Floor Opp.Nadt Nelson Square, Nagpur, Maharashtra, India – 440013, or through the website zimlab.in.